nach oben

Clinical Pharmacokinetics

Erschienen in:

01.07.2013 | Review Article

Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid

verfasst von: Antonello Di Paolo, Giovanni Gori, Carlo Tascini, Romano Danesi, Mario Del Tacca

Erschienen in: Clinical Pharmacokinetics | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

In the past 20 years, an increased discrepancy between new available antibacterials and the emergence of multidrug-resistant strains has been observed. This condition concerns physicians involved in the treatment of central nervous system (CNS) infections, for which clinical and microbiological success depends on the rapid achievement of bactericidal concentrations. In order to accomplish this aim, the choice of drugs is based on their disposition toward the cerebrospinal fluid (CSF), which is influenced by the physicochemical characteristics of antibacterials. A reduced distribution into CSF has been documented for beta-lactams, especially cephalosporins and carbapenems, on the basis of their hydrophilic nature. However, they represent a cornerstone of the majority of combined therapeutic schemes for their ability to achieve bactericidal concentrations, especially in the presence of inflamed meninges. The good tolerability of beta-lactams makes possible high daily dose intensities, which may be associated with increased probability of cure. Furthermore, the adoption of continuous infusion seems to be a fruitful option. Fluoroquinolones, namely moxifloxacin, and antituberculosis drugs, together with the agents such as linezolid, reach the highest CSF/plasma concentration ratio, which is greater than 0.8, and for most of these drugs it is near 1. For all drugs that are currently used for the treatment of CNS infections, the evaluation of pharmacokinetic/pharmacodynamic parameters, on the basis of dosing regimens and their time-dependent or concentration-dependent pattern of bacterial killing, remains an important aspect of clinical investigation and medical practice.

Taylor EM. The impact of efflux transporters in the brain on the development of drugs for CNS disorders. Clin Pharmacokinet. 2002;41(2):81–92.PubMed

Nag S, Begley DJ. Blood–brain barrier, exchange of metabolites and gases. In: Kalimo H (ed) Cerebrovascular diseases. P.a. genetics. Basel; ISN Neuropath. Press: 2005. p. 22–29.

Abbott NJ, Patabendige AA, Dolman DE, et al. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010;37(1):13–25.PubMed

Brown PD, Davies SL, Speake T, et al. Molecular mechanisms of cerebrospinal fluid production. Neuroscience. 2004;129(4):957–70.PubMed

Abbott NJ. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int. 2004;45(4):545–52.PubMed

Dolman D, Drndarski S, Abbott NJ, et al. Induction of aquaporin 1 but not aquaporin 4 messenger RNA in rat primary brain microvessel endothelial cells in culture. J Neurochem. 2005;93(4):825–33.PubMed

Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.PubMed

Redzic Z. Molecular biology of the blood–brain and the blood–cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS. 2011;8(1):3.PubMed

Hawkins BT, Davis TP. The blood–brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–85.PubMed

10.

de Boer AG, Gaillard PJ. Strategies to improve drug delivery across the blood–brain barrier. Clin Pharmacokinet. 2007;46(7):553–76.PubMed

11.

Ehrlich P. Über das Sauerstoffbedu¨rfnis des Organismus. Eine farbenanalytische Studie,1885, Berlin.

12.

Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood–cerebrospinal fluid/blood–brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858–83.PubMed

13.

Goldmann EE, Vitalfärbung am Zentralnervensystem, ed. A.P.i. Akad1913: Wiss. Phys. Math. Kl.

14.

McComb JG. Recent research into the nature of cerebrospinal fluid formation and absorption. J Neurosurg. 1983;59(3):369–83.PubMed

15.

Ghersi-Egea JF, Leininger-Muller B, Cecchelli R, et al. Blood–brain interfaces: relevance to cerebral drug metabolism. Toxicol Lett. 1995;82–83:645–53.PubMed

16.

Loscher W, Potschka H. Blood–brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2(1):86–98.PubMed

17.

Miller DS, Bauer B, Hartz AM. Modulation of P-glycoprotein at the blood–brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev. 2008;60(2):196–209.PubMed

18.

Quagliarello VJ, Wispelwey B, Long WJ Jr, et al. Recombinant human interleukin-1 induces meningitis and blood–brain barrier injury in the rat. Characterization and comparison with tumor necrosis factor. J Clin Invest. 1991;87(4):1360–6.PubMed

19.

Scheld WM, Dacey RG, Winn HR, et al. Cerebrospinal fluid outflow resistance in rabbits with experimental meningitis. Alterations with penicillin and methylprednisolone. J Clin Invest. 1980;66(2):243–53.PubMed

20.

Bauer B, Hartz AM, Miller DS. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood–brain barrier. Mol Pharmacol. 2007;71(3):667–75.PubMed

21.

Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol. 2008;4(10):1245–64.PubMed

22.

Dumas N, Seguela JP, Giroud JP. Acute nonspecific inflammatory reaction and modification of resistance to Toxoplasma gondii. Bull Soc Pathol Exot Filiales. 1984;77(2):190–5.PubMed

23.

Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 37(3):840–51 (quiz 859).

24.

Pea F. Plasma pharmacokinetics of antimicrobial agents in critically ill patients. Curr Clin Pharmacol. 2013;8(1):5–12.PubMed

25.

Hayashi Y, Lipman J, Udy AA, et al. Beta-lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents. 2013;41(2):162–6.PubMed

26.

van de Beek D, de Gans J, Spanjaard L, et al. Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 2004;351(18):1849–59.PubMed

27.

Brouwer MC, van de Beek D. Bacterial meningitis. Ned Tijdschr Tandheelkd. 2012;119(5):238–42.PubMed

28.

Eckburg PB, Montoya JG, Vosti KL. Brain abscess due to Listeria monocytogenes: five cases and a review of the literature. Medicine (Baltimore). 2001;80(4):223–35.

29.

Giamarellou H. Multidrug-resistant Gram-negative bacteria: how to treat and for how long. Int J Antimicrob Agents. 2010;36(Suppl 2):S50–4.PubMed

30.

Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis. 2010;10(1):43–50.PubMed

31.

Chaudhuri A, Martinez-Martin P, Kennedy PG, et al. EFNS guideline on the management of community-acquired bacterial meningitis: report of an EFNS Task Force on acute bacterial meningitis in older children and adults. Eur J Neurol. 2008;15(7):649–59.PubMed

32.

de Gans J, van de Beek D. European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. NEJM. 2002;347(20):8.

33.

Brouwer MC, McIntyre P, de Gans J, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2010;9:CD004405.

34.

Ricard JD, Wolff M, Lacherade JC, et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin Infect Dis. 2007;44(2):250–5.PubMed

35.

Gaillard JL, Abadie V, Cheron G, et al. Concentrations of ceftriaxone in cerebrospinal fluid of children with meningitis receiving dexamethasone therapy. Antimicrob Agents Chemother. 1994;38(5):1209–10.PubMed

36.

Buke AC, Karasulu E, Karakartal G. Does dexamethasone affect ceftriaxone (corrected) penetration into cerebrospinal fluid in adult bacterial meningitis. Int J Antimicrob Agents. 2003;21(5):5.

37.

Fernandez A, Cabellos C, Tubau F, et al. Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis. J Antimicrob Chemother. 2005;55(1):78–83.PubMed

38.

Li J, Wang LN. Zheng HY. J Eur Acad Dermatol Venereol: Jarisch-Herxheimer reaction among syphilis patients in China; 2012.

39.

Yang CJ, Lin YH, Lee HC, Ko WC, Liao CH, Wu CH, Hsieh CY, Wu PY, Liu WC, Chang YC, Hung CC. Jarisch-Herxheimer reaction after penicillin therapy among patients with syphilis in the era of the HIV infection epidemic: incidence and risk factors. Clin Infect Dis. 2010;51(8):9.

40.

Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha. N Engl J Med. 1996;335(5):311–5.PubMed

41.

Gudjonsson HSkog E. The effect of prednisolone on the Jarisch-Herxheimer reaction. Acta Derm Venereol. 1968;48(1):15–8.

42.

Butler T, Jones PK, Wallace CK. Borrelia recurrent is infection: single-dose antibiotic regimens and management of the Jarisch-Herxheimer reaction. J Infect Dis. 1978;137(5):5.

43.

Arlotti M, Grossi P, Pea F, et al. Consensus document on controversial issues for the treatment of infections of the central nervous system: bacterial brain abscesses. Int J Infect Dis. 2010;14(Suppl 4):S79–92.PubMed

44.

Sjolin J, Eriksson N, Arneborn P, et al. Penetration of cefotaxime and desacetylcefotaxime into brain abscesses in humans. Antimicrob Agents Chemother. 1991;35(12):2606–10.PubMed

45.

Green HT, O’Donoghue MA, Shaw MD, Dowling C. Penetration of ceftazidime into intracranial abscess. J Antimicrob Chemother. 1989;24(3):6.

46.

Asensi V, Carton JA, Maradona JA, et al. Therapy of brain abscess with imipenem—a safe therapeutic choice? J Antimicrob Chemother. 1996;37(1):200–3.PubMed

47.

Malacarne P, Viaggi B, Di Paolo A, et al. Linezolid cerebrospinal fluid concentration in central nervous system infection. J Chemother. 2007;19(1):90–3.PubMed

48.

Battal B, Kocaoglu M, Bulakbasi N, et al. Cerebrospinal fluid flow imaging by using phase-contrast MR technique. Br J Radiol. 2011;84(1004):8.

49.

Sommer JB, Gaul C, Heckmann J, et al. Does lumbar cerebrospinal fluid reflect ventricular cerebrospinal fluid? A prospective study in patients with external ventricular drainage. Eur Neurol. 2002;47(4):224–32.PubMed

50.

Nau R, Sorgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet. 1998;35(3):223–46.PubMed

51.

Bakken JS, Bruun JN, Gaustad P, et al. Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges. Antimicrob Agents Chemother. 1986;30(3):481–4.PubMed

52.

Viaggi B, Di Paolo A, Danesi R, et al. Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics. Scand J Infect Dis. 2011;43(9):721–7.PubMed

53.

Nau R, Lassek C, Kinzig-Schippers M, et al. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob Agents Chemother. 1998;42(8):2012–6.PubMed

54.

Tsumura R, Ikawa K, Morikawa N, et al. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. J Chemother. 2008;20(5):615–21.PubMed

55.

Imberti R, Cusato M, Accetta G, et al. Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate. Antimicrob Agents Chemother. 2012;56(8):4416–21.PubMed

56.

Cook AM, Mieure KD, Owen RD, et al. Intracerebroventricular administration of drugs. Pharmacotherapy. 2009;29(7):832–45.PubMed

57.

Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents. 2008;31(2):122–9.PubMed

58.

Thea D, Barza M. Use of antibacterial agents in infections of the central nervous system. Infect Dis Clin North Am. 1989;3(3):8.

59.

Sinner SW, Tunkel AR. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am. 2004;18(3):12.

60.

Levison ME. Pharmacodynamic of antimicrobial drugs. Infect Dis Clin North Am. 2004;18(3):15.

61.

Volpe JJ. Specialized studies in the neurological evaluation. In: Neurology of the newborn. Philadelphia; W. B. Saunders Company: 2001. p. 134–177.

62.

Blennow K, Fredman P, Wallin A, et al. Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18–88 years of age. Eur Neurol. 1993;33(2):129–33.PubMed

63.

May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI. Cerebrospinal fluid production is reduced in healthy aging. Neurology. 1990;40(3 Pt 1):4.

64.

Allegaert K, Scheers I, Adams E, et al. Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates. Antimicrob Agents Chemother. 2008;52(6):1934–9.PubMed

65.

Kohlhepp SJ, Gilbert DN, Leggett JE. Influence of assay methodology on the measurement of free serum ceftriaxone concentrations. Antimicrob Agents Chemother. 1998;42(9):2259–61.PubMed

66.

Lodise TP, Nau R, Kinzig M, et al. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation. J Antimicrob Chemother. 2007;60(5):1038–44.PubMed

67.

Decazes JM, Ernst JD, Sande MA. Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis. Antimicrob Agents Chemother. 1983;24(4):463–7.PubMed

68.

Tauber MG, Kunz S, Zak O, et al. Influence of antibiotic dose, dosing interval, and duration of therapy on outcome in experimental pneumococcal meningitis in rabbits. Antimicrob Agents Chemother. 1989;33(4):418–23.PubMed

69.

Lutsar I, Ahmed A, Friedland IR, et al. Pharmacodynamics and bactericidal activity of ceftriaxone therapy in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 1997;41(11):2414–7.PubMed

70.

Rodriguez-Cerrato V, McCoig CC, Michelow IC, et al. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob Agents Chemother. 2001;45(11):3092–7.PubMed

71.

Lutsar I, Friedland IR, Wubbel L, et al. Pharmacodynamics of gatifloxacin in cerebrospinal fluid in experimental cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother. 1998;42(10):2650–5.PubMed

72.

Nadler HL, Pitkin DH, Sheikh W. The postantibiotic effect of meropenem and imipenem on selected bacteria. J Antimicrob Chemother. 1989;24(Suppl A):225–31.

73.

Zhanel GG, Noreddin AM. Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr Opin Pharmacol. 2001;1(5):5.

74.

Zhanel GG, Karlowsky JA, Davidson RJ, et al. Effect of pooled human cerebrospinal fluid on the postantibiotic effects of cefotaxime, ciprofloxacin, and gentamicin against Escherichia coli. Antimicrob Agents Chemother. 1992;36(5):1136–9.PubMed

75.

Tessier PR, Nightingale CH, Nicolau DP. Postantibiotic effect of trovafloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis in cerebrospinal fluid and broth culture media. Diagn Microbiol Infect Dis. 2000;36(4):241–7.PubMed

76.

Sande MA, Korzeniowski OM, Allegro GM, Brennan RO, Zak O, Scheld WM. Intermittent or continuous therapy of experimental meningitis due to Streptococcus pneumoniae in rabbits: preliminary observations on the postantibiotic effect in vivo. Rev Infect Dis. 1981;3(1):12.

77.

Tauber MG, Zak O, Scheld WM, et al. The postantibiotic effect in the treatment of experimental meningitis caused by Streptococcus pneumoniae in rabbits. J Infect Dis. 1984;149(4):575–83.PubMed

78.

Meng X, Pei Y, Nightingale CH, et al. Determination of the in vivo post-antibiotic effects of ciprofloxacin and rifampicin. J Antimicrob Chemother. 1995;36(6):987–96.PubMed

79.

Wilson HD, Haltalin KC. Ampicillin in Haemophilus influenzae meningitis. Clinicopharmacologic evaluation of intramuscular vs intravenous administration. Am J Dis Child. 1975;129(2):208–15.PubMed

80.

Nau R, Prange HW, Muth P, et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob Agents Chemother. 1993;37(7):1518–24.PubMed

81.

Sauermann R, Schwameis R, Fille M, et al. Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemother. 2009;64(4):821–3.PubMed

82.

Zwijnenburg PJ, van der Poll T, Roord JJ, et al. Chemotactic factors in cerebrospinal fluid during bacterial meningitis. Infect Immun. 2006;74(3):1445–51.PubMed

83.

Tanaka M, Hoshino K, Hohmura M, et al. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method. J Antimicrob Chemother. 1996;37(6):1091–102.PubMed

84.

Schmidt T, Froula JTauber MG. Clarithromycin lacks bactericidal activity in cerebrospinal fluid in experimental pneumococcal meningitis. J Antimicrob Chemother. 1993;32(4):627–32.PubMed

85.

Kuroda M, Kusuhara H, Endou H, et al. Rapid elimination of cefaclor from the cerebrospinal fluid is mediated by a benzylpenicillin-sensitive mechanism distinct from organic anion transporter 3. J Pharmacol Exp Ther. 2005;314(2):855–61.PubMed

86.

Tomaselli F, Maier A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother. 2004;48(6):2228–32.PubMed

87.

Nicasio AM, Ariano RE, Zelenitsky SA, et al. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2009;53(4):1476–81.PubMed

88.

Ratilal BO, Costa J, Sampaio C, Pappamikail L. Antibiotic prophylaxis for preventing meningitis in patients with basilar skull fractures. Cochrane Database Syst Rev 2011;8:CD004884.

89.

Burgess DS, Frei CR, Lewis Ii JS, et al. The contribution of pharmacokinetic-pharmacodynamic modelling with Monte Carlo simulation to the development of susceptibility breakpoints for Neisseria meningitidis. Clin Microbiol Infect. 2007;13(1):33–9.PubMed

90.

(EUCAST) ECoAST. Clinical breakpoints (online). http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_Breakpoint_table_v_3.0.pdf. Accessed 2013 Jan 18.

91.

Cacho C, Brito B, Palacios J, et al. Speciation of nickel by HPLC–UV/MS in pea nodules. Talanta. 2010;83(1):78–83.PubMed

92.

Lodise TP Jr, Rhoney DH, Tam VH, et al. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. Diagn Microbiol Infect Dis. 2006;54(3):223–30.PubMed

93.

Lutsar I, Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet. 2000;39(5):335–43.PubMed

94.

Rhoney DH, Tam VH, Parker D Jr, et al. Disposition of cefepime in the central nervous system of patients with external ventricular drains. Pharmacotherapy. 2003;23(3):310–4.PubMed

95.

Lodise TP Jr, Nau R, Kinzig M, et al. Comparison of the probability of target attainment between ceftriaxone and cefepime in the cerebrospinal fluid and serum against Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2007;58(4):445–52.PubMed

96.

Jiménez Palacios FJ, Callejon Mochon M, Jiménez Sànchez JC. Validation of an HPLC method for determination of cefepime (a fourth-generation cephalosporin). Determination in human serum, cerebrospinal fluid, and urine. Pharmacokinetic profiles. Chromatographica. 2005;62(7/8):7.

97.

Latif R, Dajani AS. Ceftriaxone diffusion into cerebrospinal fluid of children with meningitis. Antimicrob Agents Chemother. 1983;23(1):46–8.PubMed

98.

Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother. 2000;45(1):5–7.PubMed

99.

Zhanel GG, Simor AE, Vercaigne L, et al. Imipenem and meropenem: comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects. Can J Infect Dis. 1998;9(4):215–28.PubMed

100.

Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027–52.PubMed

101.

Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006;46(10):1171–8.PubMed

102.

Gaillard JL, Silly C, Le Masne A, et al. Cerebrospinal fluid penetration of amikacin in children with community-acquired bacterial meningitis. Antimicrob Agents Chemother. 1995;39(1):253–5.PubMed

103.

Eisenhut M, Meehan TBatchelor L. Cerebrospinal fluid glucose levels and sensorineural hearing loss in bacterial meningitis. Infection. 2003;31(4):247–50.PubMed

104.

Alffenaar JW, van Altena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis. 2009;49(7):1080–2.PubMed

105.

Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob Chemother. 2008;61(6):1328–31.PubMed

106.

Nijland HM, Ruslami R, Suroto AJ, et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45(8):1001–7.PubMed

107.

Shandil RK, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51(2):576–82.PubMed

108.

Pranger AD, Alffenaar JW, Wessels AM, et al. Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography–tandem mass spectrometry method. J Anal Toxicol. 2010;34(3):135–41.PubMed

109.

Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011;55(7):3244–53.PubMed

110.

Pea F, Pavan F, Nascimben E, et al. Levofloxacin disposition in cerebrospinal fluid in patients with external ventriculostomy. Antimicrob Agents Chemother. 2003;47(10):3104–8.PubMed

111.

Dudhani RV, Turnidge JD, Nation RL, et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65(9):1984–90.PubMed

112.

Antachopoulos C, Karvanen M, Iosifidis E, et al. Serum and cerebrospinal fluid levels of colistin in pediatric patients. Antimicrob Agents Chemother. 2010;54(9):3985–7.PubMed

113.

Jimenez-Mejias ME, Pichardo-Guerrero C, Marquez-Rivas FJ, et al. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur J Clin Microbiol Infect Dis. 2002;21(3):212–4.PubMed

114.

Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother. 2009;53(11):4907–10.PubMed

115.

Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267–84.PubMed

116.

Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis. 2013;56(5):697–700.PubMed

117.

Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430–6.PubMed

118.

Periti P, Mazzei T, Mini E, et al. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part II). Clin Pharmacokinet. 1989;16(5):261–82.PubMed

119.

Periti P, Mazzei T, Mini E, et al. Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet. 1989;16(4):193–214.PubMed

120.

Jaruratanasirikul S, Hortiwakul R, Tantisarasart T, et al. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob Agents Chemother. 1996;40(3):825–6.PubMed

121.

Williams JD. Spectrum of activity of azithromycin. Eur J Clin Microbiol Infect Dis. 1991;10(10):813–20.PubMed

122.

Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs. 1992;44(5):750–99.PubMed

123.

Baschiera F, Fornai M, Lazzeri G, et al. Improved tonsillar disposition of azithromycin following a 3-day oral treatment with 20 mg/kg in paediatric patients. Pharmacol Res. 2002;46(1):95–100.PubMed

124.

Lucchi M, Damle B, Fang A, et al. Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin. J Antimicrob Chemother. 2008;61(4):884–91.PubMed

125.

Di Paolo A, Barbara C, Chella A, Angeletti CA, Del Tacca M. Pharmacokinetics of azithromycin in lung tissue, bronchial washing, and plasma in patients given multiple oral doses of 500 and 1000 mg daily. Pharmacol Res. 2002;46(6):6.

126.

Wallace RJ Jr, Meier A, Brown BA, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother. 1996;40(7):1676–81.PubMed

127.

Ingram CW, Tanner DC, Durack DT, et al. Disseminated infection with rapidly growing mycobacteria. Clin Infect Dis. 1993;16(4):463–71.PubMed

128.

Maniu CV, Hellinger WC, Chu SY, et al. Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid. Clin Infect Dis. 2001;33(5):745–8.PubMed

129.

Fernandes PB, Bailer R, Swanson R, et al. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide. Antimicrob Agents Chemother. 1986;30(6):865–73.PubMed

130.

Imshenetskaia VF. Erythromycin penetration into the cerebrospinal fluid of patients. Antibiotiki. 1976;21(11):1002–4.PubMed

131.

Petersen PJ, Jones CH, Bradford PA. In vitro antibacterial activities of tigecycline and comparative agents by time-kill kinetic studies in fresh Mueller-Hinton broth. Diagn Microbiol Infect Dis. 2007;59(3):347–9.PubMed

132.

Noviello S, Ianniello F, Leone S, et al. In vitro activity of tigecycline: MICs, MBCs, time-kill curves and post-antibiotic effect. J Chemother. 2008;20(5):577–80.PubMed

133.

van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000;44(4):943–9.PubMed

134.

Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51(6):1939–45.PubMed

135.

Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52(1):204–10.PubMed

136.

Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–65.PubMed

137.

Kang-Birken SL, Castel UPrichard JG. Oral doxycycline for treatment of neurosyphilis in two patients infected with human immunodeficiency virus. Pharmacotherapy. 2010;30(4):119e–22e.PubMed

138.

Psomas KC, Brun M, Causse A, et al. Efficacy of ceftriaxone and doxycycline in the treatment of early syphilis. Med Mal Infect. 2012;42(1):15–9.PubMed

139.

Johnson SE, Klein GC, Schmid GP, et al. Susceptibility of the Lyme disease spirochete to seven antimicrobial agents. Yale J Biol Med. 1984;57(4):549–53.PubMed

140.

Bernardino AL, Kaushal D, Philipp MT. The antibiotics doxycycline and minocycline inhibit the inflammatory responses to the Lyme disease spirochete Borrelia burgdorferi. J Infect Dis. 2009;199(9):1379–88.PubMed

141.

Andersson H, Alestig K. The penetration of doxycycline into CSF. Scand J Infect Dis Suppl. 1976;9:17–9.PubMed

142.

Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother. 1985;28(2):347–8.PubMed

143.

Karlsson M, Hammers S, Nilsson-Ehle I, et al. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother. 1996;40(5):1104–7.PubMed

144.

Dotevall L, Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. Antimicrob Agents Chemother. 1989;33(7):1078–80.PubMed

145.

Petersen PJ, Ruzin A, Tuckman M, et al. In vitro activity of tigecycline against patient isolates collected during phase 3 clinical trials for diabetic foot infections. Diagn Microbiol Infect Dis. 2010;66(4):407–18.PubMed

146.

Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221–9.PubMed

147.

Van Wart SA, Cirincione BB, Ludwig EA, et al. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol. 2007;47(6):727–37.PubMed

148.

Wadi JA, Al Rub MA. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann Saudi Med. 2007;27(6):456–8.PubMed

149.

Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J. 2010;29(4):379–81.PubMed

150.

Tutuncu EE, Kuscu F, Gurbuz Y, et al. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis. Int J Infect Dis. 2010;14(Suppl 3):e224–6.PubMed

151.

Lengerke C, Haap M, Mayer F, et al. Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges. Antimicrob Agents Chemother. 2011;55(1):449–50.PubMed

152.

Ray L, Levasseur K, Nicolau DP, et al. Cerebral spinal fluid penetration of tigecycline in a patient with Acinetobacter baumannii cerebritis. Ann Pharmacother. 2010;44(3):582–6.PubMed

153.

Dandache P, Nicolau, DP, Sakoulas, G. Tigecycline for the treatment of multidrug-resistant Klebsiella pneumoniae meningitis. Infect Dis Clin Pract. 2009;17(Abstract):66.

154.

van de Beek D, Brouwer M, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. Lancet. 2012;380(9854):10.

155.

Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis. 2000;30(1):146–51.PubMed

156.

Andes D, van Ogtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46(11):3484–9.PubMed

157.

Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother. 2007;51(1):379–82.PubMed

158.

Yogev R, Damle B, Levy G, et al. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J. 2010;29(9):827–30.PubMed

159.

Di Paolo A, Malacarne P, Guidotti E, et al. Pharmacological issues of linezolid: an updated critical review. Clin Pharmacokinet. 2010;49(7):439–47.PubMed

160.

Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother. 2006;50(12):3971–6.PubMed

161.

Gandelman K, Zhu T, Fahmi OA, et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol. 2011;51(2):229–36.PubMed

162.

Tsuji Y, Hiraki Y, Matsumoto K, et al. Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis. Scand J Infect Dis. 2011;43(11–12):982–5.PubMed

163.

Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48(1):63–8.PubMed

164.

Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother. 2004;48(10):3928–33.PubMed

165.

Riser MS, Bland CM, Rudisill CN, et al. Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis. Ann Pharmacother. 2010;44(11):1832–5.PubMed

166.

Kullar R, Chin JN, Edwards DJ, et al. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother. 2011;55(7):3505–9.PubMed

167.

Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev. 2010;23(3):467–92.PubMed

168.

Jourdan C, Convert J, Peloux A, et al. Adequate intrathecal diffusion of teicoplanin after failure of vancomycin, administered in continuous infusion in three cases of shunt associated meningitis. Pathol Biol (Paris). 1996;44(5):389–92.

169.

Cataldo MA, Tacconelli E, Grilli E, et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother. 2012;67(1):17–24.PubMed

170.

Pea F, Brollo L, Viale P, et al. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003;51(4):971–5.PubMed

171.

Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients. Surg Neurol. 2008;69(2):126–9 (discussion 129).

172.

Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg. 2007;43(6):449–55.PubMed

173.

Budha NR, Lee RB, Hurdle JG, et al. A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. Tuberculosis (Edinb). 2009;89(5):378–85.

174.

Peloquin CA, Jaresko GS, Yong CL, et al. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide. Antimicrob Agents Chemother. 1997;41(12):2670–9.PubMed

175.

Donald PR, Gent WL, Seifart HI, et al. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status. Pediatrics. 1992;89(2):247–50.PubMed

176.

Gumbo T, Louie A, Deziel MR, et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother. 2007;51(11):3781–8.PubMed

177.

Nau R, Prange HW, Menck S, et al. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J Antimicrob Chemother. 1992;29(6):719–24.PubMed

178.

Ellard GA, Humphries MJ, Gabriel M, et al. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br Med J (Clin Res Ed). 1987;294(6567):284–5.

179.

Phuapradit P, Supmonchai K, Kaojarern S, et al. The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis. J Neurol Neurosurg Psychiatry. 1990;53(1):81–2.PubMed

180.

Gumbo T, Dona CS, Meek C, et al. Pharmacokinetics–pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother. 2009;53(8):3197–204.PubMed

181.

Ellard GA, Humphries MJ, Allen BW. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am Rev Respir Dis. 1993;148(3):650–5.PubMed

182.

Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol. 1996;33(3):167–75.PubMed

183.

Pilheu JA, Maglio F, Cetrangolo R, et al. Concentrations of ethambutol in the cerebrospinal fluid after oral administration. Tubercle. 1971;52(2):117–22.PubMed

184.

Hughes IE, Smith H. Ethionamide: its passage into the cerebrospinal fluid in man. Lancet. 1962;1(7230):616–7.PubMed

185.

Donald PR, Seifart HI. Cerebrospinal fluid concentrations of ethionamide in children with tuberculous meningitis. J Pediatr. 1989;115(3):483–6.PubMed

186.

Baron H, Epstein IG, Mulinos MG, et al. Absorption, distribution, and excretion of cycloserine in man. Antibiot Annu. 1955;3:136–40.PubMed

187.

Pfausler B, Spiss H, Dittrich P, et al. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy-associated ventriculitis. J Antimicrob Chemother. 2004;53(5):848–52.PubMed

188.

Dudley MN, Levitz RE, Quintiliani R, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother. 1984;26(6):811–4.PubMed

189.

Misra A, Ganesh S, Shahiwala A, et al. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci. 2003;6(2):252–73.PubMed

190.

Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv. 2006;3(2):219–32.PubMed

191.

Witt KA, Gillespie TJ, Huber JD, et al. Peptide drug modifications to enhance bioavailability and blood–brain barrier permeability. Peptides. 2001;22(12):2329–43.PubMed

192.

Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7(3):255–70.PubMed

193.

Lin C, Sunkara G, Cannon JB, et al. Recent advances in prodrugs as drug delivery systems. Am J Ther. 2012;19(1):33–43.PubMed

194.

Micheli MR, Bova R, Magini A, et al. Lipid-based nanocarriers for CNS-targeted drug delivery. Recent Pat CNS Drug Discov. 2012;7(1):71–86.PubMed

195.

Liu L, Venkatraman SS, Yang YY, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood–brain barrier. Biopolymers. 2008;90(5):617–23.PubMed

196.

Marquet F, Tung YS, Teichert T, et al. Noninvasive, transient and selective blood–brain barrier opening in non-human primates in vivo. PLoS One. 2011;6(7):e22598.PubMed

197.

O’Reilly MA, Hynynen K. Blood–brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology. 2012;263(1):96–106.PubMed

198.

Liu HL, Yang HW, Hua MY, et al. Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood–brain barrier disruption for brain tumor treatment: an overview of the current preclinical status. Neurosurg Focus. 2012;32(1):E4.PubMed

199.

Etame AB, Diaz RJ, Smith CA, et al. Focused ultrasound disruption of the blood–brain barrier: a new frontier for therapeutic delivery in molecular neurooncology. Neurosurg Focus. 2012;32(1):E3.PubMed

200.

Pardridge WM. Blood–brain barrier delivery. Drug Discov Today. 2007;12(1–2):54–61.PubMed

201.

Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448(7149):39–43.PubMed

202.

Dunlop EM, Al-Egaily SS, Houang ET. Penicillin levels in blood and CSF achieved by treatment of syphilis. JAMA. 1979;241(23):3.

203.

van der Valk PG, Kraai EJ, van Voorst Vader PC, et al. Penicillin concentrations in cerebrospinal fluid (CSF) during repository treatment regimen for syphilis. Genitourin Med. 1988;64(4):223–5.PubMed

204.

Landis MS, Boyden T, Pegg S. Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective. Ther Deliv. 2012;3(2):195–208.PubMed

205.

Manda P, Hargett JK, Vaka SR, et al. Delivery of cefotaxime to the brain via intranasal administration. Drug Dev Ind Pharm. 2011;37(11):1306–10.PubMed

206.

Reesor C, Chow AW, Kureishi A, et al. Kinetics of intraventricular vancomycin in infections of cerebrospinal fluid shunts. J Infect Dis. 1988;158(5):1142–3.PubMed

207.

McCracken GH Jr, Mize SG, Threlkeld N. Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. Lancet. 1980;1(8172):787–91.PubMed

208.

Shah S, Ohlsson A, Shah V. Intraventricular antibiotics for bacterial meningitis in neonates. Cochrane Database Syst Rev. 2004;4:CD004496.

209.

Tangden T, Enblad P, Ullberg M, et al. Neurosurgical gram-negative bacillary ventriculitis and meningitis: a retrospective study evaluating the efficacy of intraventricular gentamicin therapy in 31 consecutive cases. Clin Infect Dis. 2011;52(11):1310–6.PubMed

210.

De Sarro A, Ammendola D, Zappala M, et al. Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother. 1995;39(1):232–7.PubMed

211.

Arnell K, Enblad P, Wester T, et al. Treatment of cerebrospinal fluid shunt infections in children using systemic and intraventricular antibiotic therapy in combination with externalization of the ventricular catheter: efficacy in 34 consecutively treated infections. J Neurosurg. 2007;107(3 Suppl):213–9.PubMed

212.

Nau R, Prange HW, Kinzig M, et al. Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies. Antimicrob Agents Chemother. 1996;40(3):763–6.PubMed

213.

Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2008;47(3):303–27.PubMed

Titel: Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid
verfasst von: Antonello Di Paolo
Giovanni Gori
Carlo Tascini
Romano Danesi
Mario Del Tacca
Publikationsdatum: 01.07.2013
Verlag: Springer International Publishing AG
Erschienen in: Clinical Pharmacokinetics / Ausgabe 7/2013
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI: https://doi.org/10.1007/s40262-013-0062-9

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Clinical Pharmacokinetics of Antibacterials in Cerebrospinal Fluid

Abstract

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2013

Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer

Erratum to: A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults

Simultaneous Pharmacogenetics-Based Population Pharmacokinetic Analysis of Darunavir and Ritonavir in HIV-Infected Patients

Prediction of drug-drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach

A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to Adults

Erratum to: Prediction of Drug–Drug Interactions Between Various Antidepressants and Efavirenz or Boosted Protease Inhibitors Using a Physiologically Based Pharmacokinetic Modelling Approach